breckgamel

We are excited to announce our latest Center of Excellence, Baylor Scott and White, The Heart Hospital in Dallas, Texas. Congratulations on this huge accomplishment! 👏

Just when you think the action is over.. on the other side of @ReunionTower another great job by Dallas finest @DallasPD @wfaa

Wild view from @ReunionTower Shout out to the @DallasFireRes_q team!! @wfaa

And we hope PERT will help reducing this serious complication of PE💪🏻💪🏻 #PERT2025 @PERTConsortium

Traveling after #DVT and #PE require caution due to physiological changes during flights - presentation by Dr. Phil Wells @PERTConsortium #PERT2025 #VTE

A rewarding surprise of CoE: hospital administrators not only supported the accreditation but offered unexpected praise throughout the process—recognizing the hard work behind PERTs. #PERT2025 #PECOE 🫁

Why PE Center of Excellence Matters @PERTConsortium #PERT2025

“The best strategy to manage an anticoagulation-related bleed🩸 ? PREVENT IT, by minimizing risk in advance!” says Dr. George Davis at #PERT2025 along with a discussion of updates on reversal agents

Common myths of LMWH vs UFH use highlighted by @bhwords along with advice on leveraging the unique qualities of each agent for each clinical scenario! #PERT2025 #PERTtrainee

Prevention of AC-related Bleeding is the # 1 way to Treat it! Anticoagulation stewardship should be a 🔑 part of all thrombosis programs. Great talk by George Davis @PERTConsortium #PERT2025

LMWH is more efficacious, safer and easier to manage than UFH in acute VTE. DOACs are effective, safe, more convenient than LMWH/warfarin. Apixaban offers lower bleeding rate than Rivaroxaban. Presentation by Beverly Hunt @PERTConsortium #PERT2025

Unfractionated heparin (UFH) vs. Low Molecular Weight Heparin (LMWH) presentation by Beverly Hunt, OBE from St Thomas’ Hospital @PERTConsortium #PERT2025

This is why adequately addressing #PE matters. Long term impact of #pulmonaryembolism can significantly negatively affect health and quality of life. @PERTConsortium #PERT2025

We know well how to differentiate between high-risk and low-risk #PE. The heterogeneity of intermediate-risk PE makes management challenging. What tools do we have for nuanced classification and to improve outcomes? Dr. Timothy Morris @UCSDHealth explains at #PERT2025

Honest conclusion 😀 #PERT2025 @PERTConsortium

Great presentation from @drandrewsharp ending his talk by saying we don’t know (audience chuckled) and encouraging additional work in the field @PERTConsortium #PERT2025

Not all intermediate-risk #PE is the same. Does this warrant different therapeutic approaches? @drandrewsharp explains at #PERT2025

Up next: Presentation by Dr. Andrew SP Sharp: “Does Intermediate-High versus Intermediate-Low Risk PE Warrant a Change in Therapy?” #PERT2025 @PERTConsortium

Reason for use of risk stratification: “Gestalt is not something we can 100% we can rely on.” @PERTConsortium @klinelab #PERT2025

Why is risk stratification sometimes not used in #PE? Great presentation from @klinelab @PERTConsortium #PERT2025